Comparative Pharmacology
Head-to-head clinical analysis: LOCORTEN versus SOLATENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCORTEN versus SOLATENE.
LOCORTEN vs SOLATENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Solatene is a carotenoid that acts as an antioxidant and a precursor to vitamin A. It is thought to absorb light and protect the skin from UV-induced damage, though its exact mechanism in erythropoietic protoporphyria (EPP) involves increasing skin tolerance to sunlight by reducing photosensitivity.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
Intravenous: 200 mg bolus over 5 minutes, then 1.6 mg/min continuous infusion for 24 hours. Oral: 80 mg three times daily.
None Documented
None Documented
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged up to 20-30 hours in end-stage renal disease
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Approximately 65% renal (unchanged drug) and 35% hepatic metabolism followed by biliary/fecal elimination. Renal excretion via glomerular filtration and active tubular secretion
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid